Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza virus vector COVID-19 vaccine
- Development stage
- Approved
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
The influenza virus vector COVID-19 vaccine is a viral vector-based vaccine candidate that uses an engineered influenza virus as the delivery vehicle to express antigens from SARS-CoV-2, specifically the spike protein or its receptor-binding domain (RBD). This approach leverages the established safety and immunogenicity profile of live attenuated influenza vaccines while introducing genetic material encoding SARS-CoV-2 antigens. The goal is to induce both humoral and cellular immune responses against COVID-19. Preclinical studies have shown that a single immunization can elicit strong neutralizing antibody responses and provide protection in animal models. Clinical trials have evaluated intranasal administration of this platform, with at least one phase II trial registered for an intranasal spray formulation[7].
- Other names
- influenza virus-vectored COVID-19 vaccineIFV-COV-2 S RBDIFV-COV2 S RBDIFV-COV 2 S RBD
02
Targets
Spike-ACE2 PPI (SARS-CoV-2 spike–ACE2 interface)SARS-CoV-2 spike
Beyond the preview
Go deeper on influenza virus vector COVID-19 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza virus vector COVID-19 vaccine.